Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene Sets Sights On Becoming Inflammation and Immunology Power Player

Executive Summary

Celgene will buy Receptos for $7.2 billion, gaining the late-stage drug ozanimod in development for multiple sclerosis and ulcerative colitis. With the addition of ozanimod, the company will have three late-stage drugs in its inflammation and immunology portfolio.

You may also be interested in...



Celgene Plots Blockbuster Course For Ozanimod

Celgene, in need of good news, posted positive data on a potential blockbuster for multiple sclerosis at the joint ECTRIMS-ACTRIMS meeting. Ozanimod could have important safety and tolerability advantages over Gilenya, but investors already were expecting good news.

Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends

Celgene will stop late-stage testing of its investigative therapy mongersen for Crohn’s disease after a data monitoring committee said it would be futile to continue.

Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization

A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS057009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel